Discovery of a junctional epitope antibody that stabilizes IL-6 and gp80 protein:protein interaction and modulates its downstream signaling

 

Ralph Adams, Rebecca J. Burnley, Chiara R. Valenzano, Omar Qureshi, Carl Doyle, Simon Lumb, Maria del Carmen Lopez, Robert Griffin, David McMillan, Richard D. Taylor, Chris Meier, Prashant Mori, Laura M. Griffin, Ulrich Wernery, Jörg Kinne, Stephen Rapecki, Terry S. Baker, Alastair D. G. Lawson, Michael Wright & Anna Ettorre

Scientific Reports
2017 vol: 7 Article number: 37716 doi:10.1038/srep37716

Abstract

Protein:protein interactions are fundamental in living organism homeostasis. Here we introduce VHH6, a junctional epitope antibody capable of specifically recognizing a neo-epitope when two proteins interact, albeit transiently, to form a complex. Orthogonal biophysical techniques have been used to prove the “junctional epitope” nature of VHH6, a camelid single domain antibody recognizing the IL-6–gp80 complex but not the individual components alone. X-ray crystallography, HDX-MS and SPR analysis confirmed that the CDR regions of VHH6 interact simultaneously with IL-6 and gp80, locking the two proteins together. At the cellular level, VHH6 was able to alter the response of endothelial cells to exogenous IL-6, promoting a sustained STAT3 phosphorylation signal, an accumulation of IL-6 in vesicles and an overall pro-inflammatory phenotype supported further by transcriptomic analysis. Junctional epitope antibodies, like VHH6, not only offer new opportunities in screening and structure-aided drug discovery, but could also be exploited as therapeutics to modulate complex protein:protein interactions.

View Publication

Topics: SPR, Antibodies, Monolith – MicroScale Thermophoresis, MST, Proteins, Publications

 

 

Previous Article
DNA nanostructure sequence-dependent binding of organophosphates
DNA nanostructure sequence-dependent binding of organophosphates

Up next
Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen
Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen

Ready to characterize your most challenging interactions?

Discover tools to measure binding affinity

Learn more